Sarcoma  >>  aldoxorubicin (INNO-206)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
aldoxorubicin (INNO-206) / LadRx
NCT01514188 / 2011-004927-11: Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Completed
2
126
Europe, US, RoW
INNO-206, DOXO-EMCH, Doxorubicin
ImmunityBio, Inc.
Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
04/14
12/14
NCT02029430: A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

Completed
2
15
US
50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin
ImmunityBio, Inc.
Kaposi's Sarcoma, HIV Positive, AIDS
04/16
04/16
NCT02235701: Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

Completed
1/2
70
US
170 mg/m2 aldoxorubicin, 250 mg/m2 aldoxorubicin
ImmunityBio, Inc.
Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
05/18
05/18

Download Options